Save Product
Product Details
Synonyms
TIGIT, VSIG9, VSTM3
Source
Biotinylated Human TIGIT, Fc,Avitag (TIT-H82F1) is expressed from human 293 cells (HEK293). It contains AA Met 22 - Pro 141 (Accession # Q495A1-1).
Predicted N-terminus: Met 22
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 41.3 kDa. The protein migrates as 45-55 kDa under reducing (R) condition, and 85-115 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
Labeling
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Protein Ratio
Passed as determined by the SABA assay / HABA assay / binding ELISA.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Biotinylated Human TIGIT, Fc,Avitag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
SEC-MALS
The purity of Biotinylated Human TIGIT, Fc,Avitag (Cat. No. TIT-H82F1) is more than 85% and the molecular weight of this protein is around 95-115 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Human CD155, Fc Tag (Cat. No. CD5-H5251) at 5 μg/mL (100 μL/well) can bind Biotinylated Human TIGIT, Fc,Avitag (Cat. No. TIT-H82F1) with a linear range of 10-156 ng/mL (QC tested).
Protocol
Serial dilutions of Human TIGIT Neutralizing antibody were added into Human CD155, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. CD5-H5254): Biotinylated Human TIGIT, Fc,Avitag (Cat. No. TIT-H82F1) binding reactions. The half maximal inhibitory concentration (IC50) is 0.08116 μg/mL (Routinely tested).
Protocol
Serial dilutions of Human TIGIT Neutralizing antibody were added into Human CD155, Fc Tag (Cat. No. CD5-H5251): Biotinylated Human TIGIT, Fc,Avitag (Cat. No. TIT-H82F1) binding reactions. The half maximal inhibitory concentration (IC50) is 0.06065 μg/mL (Routinely tested).
Protocol
Bioactivity-Flow Cytometry
FACS assay shows Biotinylated Human TIGIT, Fc,Avitag (Cat. No. TIT-H82F1) can bind to 293T cell overexpressing human CD155. The concentration of TIGIT is 0.03 μg/mL (Routinely tested).
Protocol
Customer Reviews Writing Reviews
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Background
Recent Advances
Drug Development Progress- English Name：
T cell immunoglobulin and ITIM domains
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
41 Details
- Highest Development Stage：
Phase 3 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
